Profil
Donald Emil Ganem currently works in Via Nova Therapeutics, Inc. as the President, Chief Executive Officer & Director.
Postes actifs de Donald Emil Ganem
| Sociétés | Poste | Début |
|---|---|---|
Via Nova Therapeutics, Inc.
 Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Via Nova Therapeutics, Inc.
Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Health Technology |
